https://www.proactiveinvestors.com.au Proactiveinvestors RSS feed en Sat, 17 Nov 2018 06:09:32 +1100 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[News - Immuron’s shares surge on demonstrating proof of concept for liver drug candidate ]]> https://www.proactiveinvestors.com.au/companies/news/192811/immurons-shares-surge-on-demonstrating-proof-of-concept-for-liver-drug-candidate-192811.html Immuron Limited’s (ASX:IMC) (NASDAQ:IMRN) IMM-124E has demonstrated a statistically significant reduction in serum lipopolysaccharide (LPS) levels, a major factor in liver inflammation.

The company’s shares were last trading circa 54% higher intra-day, at $0.44.

A total of 133 non-alcoholic steatohepatitis (NASH) patients were enrolled into Immuron’s phase II NASH clinical study and were treated with either IMM-124E or placebo for 6 months.

Results demonstrate a statistically significant reduction of serum LPS levels

64.29% of patients treated with IMM-124E demonstrated a 15% or greater decrease in serum LPS levels compared with only 34.48% of patients showing a decrease for the placebo group, reaching statistical significance.

Importantly, no safety concerns or serious adverse events were associated with the study drug.

The 600mg and 1200mg doses were well tolerated and support the use of even higher doses and extended treatment periods in future clinical trials.

Wider scope across a broad range of diseases

Immuron’s study results offer evidence of a therapeutic mechanism of action and a clear direction for further NASH studies.

The growing literature implicating LPS in many diseases offers the potential for a much wider scope for LPS antagonism as a treatment modality.

With IMM-124E being the world’s first-in class oral LPS antagonist, the company has substantial opportunities across a broad range of diseases.

READ: Immuron achieves strong sales growth for travellers’ diarrhoea product

The company’s flag-ship product Travelan® achieved a revenue in excess of $914,000 for the first six months of FY2018, experiencing strong sales growth in both the U.S. and Australia.

Travelan is a natural product, specifically designed to reduce the risk of infection by E.coli, the most common cause of travellers’ diarrhoea or Bali Belly.

]]>
Thu, 08 Mar 2018 14:17:00 +1100 https://www.proactiveinvestors.com.au/companies/news/192811/immurons-shares-surge-on-demonstrating-proof-of-concept-for-liver-drug-candidate-192811.html
<![CDATA[News - Immuron achieves strong sales growth for travellers’ diarrhoea product ]]> https://www.proactiveinvestors.com.au/companies/news/191747/immuron-achieves-strong-sales-growth-for-travellers-diarrhoea-product-191747.html Immuron Limited’s (ASX:IMC) (NASDAQ:IMRN) flag-ship product Travelan® has achieved a revenue in excess of $914,000 for the first six months of FY2018, experiencing strong sales growth in both the U.S. and Australia.

Travelan is a natural product, specifically designed to reduce the risk of infection by E.coli, the most common cause of travellers’ diarrhoea or Bali Belly.

The company sold $335,000 worth of Travelan in the U.S. market during H1 FY2018, representing a 250% increase on the same period last year.

Travelan had $579,000 in sales in the Australian market, representing a 27% increase on the same period last year.

New clinical study of IMM-529

Immuron is also developing and commercializing other oral immunetherapeutics for the treatment of gut related diseases.

Last month, the company enrolled the first patients into its first-in-human IMM-529 clinical study for the treatment of clostridium difficile infection (CDI).

Most commonly affecting older adults after use of antibiotic medications, CDI can cause symptoms that range from diarrhea to life-threatening gut inflammation.

IMM-529 uses a combination of polyclonal antibodies to target and neutralise the three main virulence factors of CDI without negatively impacting the microbiome.

Clostridium-difficile infection is a multi-billion dollar market

According to the Centers for Disease Control and Prevention (CDC), clostridium-difficile infects more than 450,000 patients causing over 29,000 deaths per year in the U.S alone.

There is a high likelihood for recurrence of symptoms, which nearly triples the healthcare costs per patient, resulting in annual healthcare costs of nearly $4.5 billion.

]]>
Fri, 16 Feb 2018 13:40:00 +1100 https://www.proactiveinvestors.com.au/companies/news/191747/immuron-achieves-strong-sales-growth-for-travellers-diarrhoea-product-191747.html
<![CDATA[News - Immuron concludes promising fatty liver disease clinical study ]]> https://www.proactiveinvestors.com.au/companies/news/187020/immuron-concludes-promising-fatty-liver-disease-clinical-study-187020.html Immuron Ltd (ASX:IMC, NASDAQ:IMRN) has concluded the phase II study of IMM‐124E for the treatment of NASH (non-alcoholic steatohepatitis), with the results expected in Q1 2018.

NASH is also known as non-alcoholic fatty liver disease.

The last patient in the clinical study conducted the final scheduled visit on October 9, following a 28‐week study period. The study enrolled a total of 133 patients with biopsy‐proven NASH.

On October 18, the study site conducted its close‐out visit.

This effectively concludes patient dosing and research activities at all study sites for the Phase II study. 

Immuron will report its top line clinical trial results in Q1 of calendar year 2018, once all data is finalised and reviewed by the company and its scientific advisory board.

Once reported, Immuron will continue its partnering and business development efforts to reach the next phase of clinical studies.

In July 2017, the company revealed interim analysis results, in which IMM‐124 demonstrated a statistically‐significant reduction in two enzymes found in the liver, compared to the placebo.

These preliminary results suggested a reduction in liver injury over the duration of treatment compared to the placebo.

]]>
Fri, 10 Nov 2017 07:45:00 +1100 https://www.proactiveinvestors.com.au/companies/news/187020/immuron-concludes-promising-fatty-liver-disease-clinical-study-187020.html
<![CDATA[News - Immuron set to commence Clostridium Difficile Infection study in Israel ]]> https://www.proactiveinvestors.com.au/companies/news/182161/immuron-set-to-commence-clostridium-difficile-infection-study-in-israel-182161.html Immuron (ASX:IMC, NASDAQ:IMRN) has been granted final approval to begin its first in-human, clinical study for the treatment of C.Difficile Infection (CDI).

CDI is a condition, acute especially in hospitals and in long-term in-patient care facilities due to bacterial toxin causing inflammation of the colon resulting in diarrhoea and in severe cases, death.

This is Immuron's first human clinical study using its IMM-529 product, following the results reported from a series of pre-clinical efficacy studies completed at Monash University.

READ: Immuron targets cash injection

IMM-529 is a naturally produced biological antibody product intended to prevent and treat CDI and designed to spare the gut microbiome from the effects of classic antibiotic treatments.

The new study is to be conducted at the Hadassah Medical Center in Jerusalem. Approval has been granted by the Hadassah Medical Center Ethics Committee and the Israeli Ministry of Health.

Immuron's clinical trial is designed to study a total of 60 patients diagnosed with CDI and have received standard of care antibiotic treatment.

Patients will be enrolled within three weeks of their diagnosis and will be randomised into either IMM-529 three times daily, or placebo, for 28 days.

The primary objective of the study is to assess IMM-529's safety and tolerability.

Immuron’s secondary endpoints are to evaluate the preliminary efficacy of IMM-529 as evaluated by the duration and severity of the symptoms and rate of disease recurrence.

]]>
Wed, 09 Aug 2017 11:58:00 +1000 https://www.proactiveinvestors.com.au/companies/news/182161/immuron-set-to-commence-clostridium-difficile-infection-study-in-israel-182161.html
<![CDATA[News - Immuron targets cash injection ]]> https://www.proactiveinvestors.com.au/companies/news/178939/immuron-targets-cash-injection-178939.html Immuron (ASX:IMC) has been granted a trading halt by the ASX, pending details of a capital raising.

Immuron is developing and commercialising oral immunotherapeutics for the treatment of many gut mediated diseases.

The halt will remain in place until the opening of trade on Tuesday 13th June 2017, or earlier if an announcement is made to the market.

]]>
Thu, 08 Jun 2017 12:00:00 +1000 https://www.proactiveinvestors.com.au/companies/news/178939/immuron-targets-cash-injection-178939.html
<![CDATA[News - Immuron looks to NASDAQ ]]> https://www.proactiveinvestors.com.au/companies/news/178442/immuron-looks-to-nasdaq-178442.html Immuron (ASX:IMC) has been granted a trading halt by the ASX, with its shares placed in pre-open.

Immuron requested the halt expects to make an update regarding a proposed US NASDAQ Initial Public Offer.

The halt will remain in place until the opening of trade on Thursday 1st June 2017, or earlier if an announcement is made to the market.

]]>
Tue, 30 May 2017 10:30:00 +1000 https://www.proactiveinvestors.com.au/companies/news/178442/immuron-looks-to-nasdaq-178442.html
<![CDATA[News - Immuron gets ready to begin clinical trial of new drug candidate ]]> https://www.proactiveinvestors.com.au/companies/news/177552/immuron-gets-ready-to-begin-clinical-trial-of-new-drug-candidate-177552.html Immuron (ASX:IMC) has successfully manufactured trial supplies of its clinical candidate IMM-529, an oral immunotherapeutic targeting the prevention of clostridium difficile Infection (CDI).

CDI results from disruption of normal, healthy bacteria in the colon, often as a result of antibiotics.

IMM-529 is a biological product which is intended to prevent and treat CDI without destroying the microbiome like antibiotic treatments, allowing the microbiome to return to a healthy state.

The antibodies survive transit through the stomach and remain functional in the large intestine.

IMM-529 was manufactured by the Commonwealth Scientific and Industrial Research Organisation (CSIRO) Separations Science team and Pharmaceutical Packaging Professionals.

Human safety and efficacy studies (Phase 1/2 clinical trial) of IMM-529 will start by the end of Q2 2017, and will aim to build on positive pre-clinical results.

These results were reported from a series of proof-of-concept efficacy studies completed by Dr. Dena Lyras and her research team at the Monash University in Melbourne.

CDI has become a major-medical problem causing an estimated annual economic cost of more than US$10 billion globally.

The problem is especially acute in hospitals and in long-term in-patient care facilities.

An estimated 29,000 patients die each year from CDI in the U.S. alone. Recurrent CDI affects circa 100,000 people in the U.S. annually.

Immuron’s share price has more than doubled since the start of 2017, last trading at $0.55.

]]>
Wed, 10 May 2017 15:00:00 +1000 https://www.proactiveinvestors.com.au/companies/news/177552/immuron-gets-ready-to-begin-clinical-trial-of-new-drug-candidate-177552.html
<![CDATA[News - Immuron enrols first patient in paediatric fatty liver trial in the U.S. ]]> https://www.proactiveinvestors.com.au/companies/news/172678/immuron-enrols-first-patient-in-paediatric-fatty-liver-trial-in-the-us-172678.html Immuron (ASX:IMC) has enrolled the first patient for its paediatric NAFLD (non-alcoholic fatty liver disease) Phase II trial conducted by Emory University in Georgia, U.S.

This Phase II, double blind, randomized study is designed to assess the safety and efficacy of Immuron’s IMM-124E for the treatment of paediatric NAFLD.

Paediatric NAFLD is a progressive form of liver disease associated with excessive fat storage in the liver together with inflammation, which can then lead to liver fibrosis and cirrhosis.

IMM-124E works upstream, and on several pathways, to reduce liver inflammation and is a unique treatment option compared to other leading investigational agents.

The principal objective of this study is to evaluate whether 12 weeks of IMM-124E treatment in children with confirmed NALFD will decrease serum ALT.

The study aims to enrol 40 paediatric patients.

Paediatric NAFLD is believed to affect up to 5% - 10% of the U.S. paediatric population.

A U.S. landmark study that examined the incidence of the disease in 742 children found that 17.3% of children aged 15 to 19 years had NAFLD.

There are currently no treatments approved for paediatric NAFLD.

Immuron’s share price has increased about 11% since the start of 2017, last trading at $0.30.

]]>
Mon, 06 Feb 2017 18:00:00 +1100 https://www.proactiveinvestors.com.au/companies/news/172678/immuron-enrols-first-patient-in-paediatric-fatty-liver-trial-in-the-us-172678.html
<![CDATA[News - Immuron watches several high-value NASH related deals ]]> https://www.proactiveinvestors.com.au/companies/news/171360/immuron-watches-several-high-value-nash-related-deals-171360.html Gilead (NASDAQ:GILD) has paid a $100 million milestone payment to Phenex following its licensing deal of Phenex’s Farnesoid X Receptor NASH Phase I clinical program in 2015.

This latest NASH milestone payment re-affirms Immuron’s belief that the LM&A market surrounding NASH technologies will remain extremely attractive, and active, for the foreseeable future.

The company’s long-term strategy is to secure a partner at the right time for its fatty-liver program.

Immuron is currently running three Phase II clinical trials in fatty-liver diseases with its lead product candidate IMM-124E including NASH, ASH (Alcoholic Steatohepatitis) and Pediatric NASH.

Both the ASH and Pediatric NASH trials are funded by the U.S. National Institutes of Health (NIH).

IMM-124E works upstream, and on several pathways, to reduce liver inflammation and is thus a completely unique treatment option compared to other leading investigational agents.

IMM-124E has the potential to be one of the backbone therapies for NASH patients.

As the worldwide prevalence of obesity and diabetes reaches epidemic proportions, the unmet need for treatments continues to grow.

In 2015, Pharmaxis’ NASH assets (Phase 1) were licensed by Boehringer ingelheim for a total potential deal value of US$600 million.

]]>
Tue, 10 Jan 2017 07:30:00 +1100 https://www.proactiveinvestors.com.au/companies/news/171360/immuron-watches-several-high-value-nash-related-deals-171360.html
<![CDATA[News - Immuron Ltd to develop vaccine for deadly bacillary dysentery with U.S. Army research unit ]]> https://www.proactiveinvestors.com.au/companies/news/137165/immuron-ltd-to-develop-vaccine-for-deadly-bacillary-dysentery-with-us-army-research-unit-69338.html Immuron Ltd (ASX:IMC) will collaborate with the Walter Reed Army Institute of Research (WRAIR) in the U.S to develop a vaccine to fight the often deadly Shigellosis, also known as bacillary dysentery.

There is currently no approved vaccine for bacillary dysentery, which is ranked number two in the 2015 Global Rank List of Infectious Disease Threats for the U.S. military.

It also results in one million deaths annually - according to a World Health Organisation report.

The symptoms include diarrhea (often bloody), fever and stomach cramps starting a day or two after exposure.

Based in Silver Spring, Maryland, and established in 1893, the Walter Reed Army Institute of Research (WRAIR)
is the oldest, largest, and most diverse military biomedical research institute within the U.S. Department of Defense.

The research and development collaboration agreement with the largest military biomedical research facility in the U.S. highlights the promise of Immuron’s oral immunotherapy platform.

One of WRAIR’s missions is to develop therapeutics for the prevention and the treatment of infectious diseases.

The long term goal of this collaboration is to develop therapeutics that can be utilized for both commercial and government use.

Immuron generated growing revenues from OTC products of $1.1 million in FY2015 and the company has forecast that its Travelan product will generate revenues of $4.6 million in FY 2017.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Tue, 21 Jun 2016 14:30:00 +1000 https://www.proactiveinvestors.com.au/companies/news/137165/immuron-ltd-to-develop-vaccine-for-deadly-bacillary-dysentery-with-us-army-research-unit-69338.html
<![CDATA[News - Immuron Ltd in ASX trading halt ]]> https://www.proactiveinvestors.com.au/companies/news/137164/immuron-ltd-in-asx-trading-halt-68870.html Immuron Ltd (ASX:IMC) has been granted a trading halt by the ASX, with its shares placed in pre-open.

The halt was requested pending details of a capital raising via a rights issue.

The halt will remain in place until the opening of trade on Tuesday 31st May 2016, or earlier if an announcement is made to the market.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Fri, 27 May 2016 12:00:00 +1000 https://www.proactiveinvestors.com.au/companies/news/137164/immuron-ltd-in-asx-trading-halt-68870.html
<![CDATA[News - Immuron Ltd has no safety issues in Phase II fatty liver trial ]]> https://www.proactiveinvestors.com.au/companies/news/137163/immuron-ltd-has-no-safety-issues-in-phase-ii-fatty-liver-trial-68826.html Biopharmaceutical company Immuron Ltd (ASX:IMC) has successfully reached the 50% recruitment milestone for the company’s phase II clinical trial for the treatment of Non-Alcoholic Steatohepatitis (fatty liver disease).

Immuron now has a total of 28 active clinical study sites across the USA, Australia and Israel with 56 patients having been randomised.

Significantly the 25 patients successfully completed treatment with its proprietary compound IMM-124E with no significant adverse effects or safety issues reported.

Immuron is expected to complete the recruitment during the second half of 2016.

The company currently markets and sells Travelan tablets for the prevention of Travellers’ diarrhoea and Protectyn, a natural dietary supplement.

Immuron is aggressively marketing the products, signing up with QBID of China earlier this month to tap into the multi-million dollar Chinese market.

QBID is an official partner of JD.com, China's largest online direct sales company, for products sourced from Australia and New Zealand.

In addition to the Chinese deal, Immuron had executed a North American distribution agreement last month with McKesson Corporation (NYSE:MCK), the largest healthcare distribution company in the world with US$179 billion revenue in 2015.

The company currently markets and sells Travelan® for the prevention of travellers’ diarrhoea which is now distributed through CVS Pharmacies - one of the largest retailers in the U.S.

Immuron had a cash balance of $994,151 as on 31 December, 2015.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Thu, 26 May 2016 10:30:00 +1000 https://www.proactiveinvestors.com.au/companies/news/137163/immuron-ltd-has-no-safety-issues-in-phase-ii-fatty-liver-trial-68826.html
<![CDATA[News - Immuron Ltd tap into U.S. market for travellers’ tablets with CVS Pharmacy ]]> https://www.proactiveinvestors.com.au/companies/news/137162/immuron-ltd-tap-into-us-market-for-travellers-tablets-with-cvs-pharmacy-68085.html Immuron Ltd (ASX:IMC), makers of Travelan tablets for the prevention of travellers’ diarrhoea, has launched Travelan through CVS Pharmacy (NYSE:CVS) in the U.S.

CVS Pharmacy is the second largest pharmacy chain in the United States after Walgreens (NASDAQ:WBA).

Travelan will be available in nearly 1,000 CVS pharmacies across the US by late May 2016.

The initial order will be for several thousand units which will be supported by targeted pull-through marketing initiatives for the product’s introduction into the CVS retail channel.

Travelan is marketed as a dietary supplement in the U.S., allowing it to be sold in pharmacies, drug stores and general stores.

In February 2016, Immuron received a cash refund of A$1,469,763 in the form of research and development tax concessions for the 2015 financial year.

In February, the company also executed a funding agreement with a New York-based investment fund to provide A$1.7 million in funding to Immuron.

 

Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.

]]>
Fri, 15 Apr 2016 11:30:00 +1000 https://www.proactiveinvestors.com.au/companies/news/137162/immuron-ltd-tap-into-us-market-for-travellers-tablets-with-cvs-pharmacy-68085.html
<![CDATA[News - Immuron receives R&D tax refund ]]> https://www.proactiveinvestors.com.au/companies/news/137161/immuron-receives-rd-tax-refund-66872.html Immuron (ASX:IMC) has received $1,469,763 in a cash refund from a Research & Development programs during 2015 in the form of tax concessions.

The Incentive refund is a tax concession for Australian biotechnology companies to fund ongoing research and development pipelines and advance promising programs.

Immuron’s marketed product, Travelan, is for the prevention of travellers’ diarrhoea, while its lead product candidate IMM-124E is in Phase 2b clinical trials for NASH and ASH.

The company focuses on commercialising oral immunotherapeutics for the treatment of a many gut mediated diseases.


Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.

]]>
Thu, 04 Feb 2016 17:00:00 +1100 https://www.proactiveinvestors.com.au/companies/news/137161/immuron-receives-rd-tax-refund-66872.html
<![CDATA[News - Immuron Limited signs U.S. distribution agreement for diarrhoea treatment ]]> https://www.proactiveinvestors.com.au/companies/news/137160/immuron-limited-signs-us-distribution-agreement-for-diarrhoea-treatment-63816.html Immuron Limited (ASX:IMC) has executed the first major non-exclusive distribution agreement in the U.S. for its Travelan diarrhoea treatment with Traveler’s Supply Inc.

Traveler’s Supply, which specialises in domestic and international travel-related products, has contracted for a minimum annual purchase volume of 50,000 units.

This follows the company making its initial U.S. sales in April 2015 to the country’s largest travel medicine chain with over 240 clinics providing travel medicine services.

Immuron’s Travelan is marketed as a dietary supplement in the U.S., allowing it to be sold in pharmacies, drug stores and general stores.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Tue, 04 Aug 2015 14:30:00 +1000 https://www.proactiveinvestors.com.au/companies/news/137160/immuron-limited-signs-us-distribution-agreement-for-diarrhoea-treatment-63816.html
<![CDATA[News - Immuron Limited accelerating recruitment for liver disease trial ]]> https://www.proactiveinvestors.com.au/companies/news/137159/immuron-limited-accelerating-recruitment-for-liver-disease-trial-63250.html Immuron Limited (ASX:IMC) is progressing recruitment for the clinical trial of its fatty liver disease treatment.

Of the 19 sites initiated globally for the Phase 2 trial of IMM-124E, 13 are in the U.S. and six are in Australia.

Three additional site, two in Israel and one in the U.S., are in the process of being initiated, which will bring the total clinical sites to 21 over the coming months.

The study will enrol a total of 120 patients with liver biopsy confirmed Non Alcoholic Steatohepatitis (NASH), a progressive form of non-alcoholic fatty liver disease characterised by fat buildup in the liver and chronic inflammation.

NASH may progress to cirrhosis, liver failure and even cancer. Its prevalence is increasing globally, associated with rising obesity, dyslipidemia and type 2 diabetes.   

The primary objectives of the study are to evaluate the safety and preliminary efficacy of IMM-
124E. IMM-124E will be compared to placebo in its potential to reduce liver fat and serum liver enzymes.

Patients randomised into the study will be orally administered either 600mg or 1,200mg doses of the study drug IMM-124E or placebo 3 times daily for 6 months. To date 33 patients had been entered into the study with ten continuing on to randomisation and dosing.

Immuron is working closely with its principle investigators and key opinion leaders to develop initiatives to drive recruitment with the aim of having the trial fully recruited by the end of 2015.



Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Thu, 02 Jul 2015 13:00:00 +1000 https://www.proactiveinvestors.com.au/companies/news/137159/immuron-limited-accelerating-recruitment-for-liver-disease-trial-63250.html
<![CDATA[News - Immuron starts sponsored Phase 2 trial for treatment of alcoholic steatohepatitis ]]> https://www.proactiveinvestors.com.au/companies/news/137158/immuron-starts-sponsored-phase-2-trial-for-treatment-of-alcoholic-steatohepatitis-60112.html Immuron Limited (ASX:IMC) has started the fully sponsored Phase 2 clinical trial in the U.S. for the treatment of alcoholic steatohepatitis (ASH) using its IMM-124E treatment.

IMM-124E is one of three therapeutic candidates selected by the United States National Institutes of Health (NIH) from 27 therapeutic candidates to be trailed for the treatment of ASH.

The trial is sponsored and funded by the US NIH and is expected to provide data that will complement Immuron’s non-alcoholic steatohepatitis (NASH) clinical development program

IMM-124E is a natural product for the treatment of fatty liver associated with ASH and NASH. IMM-124E contains the natural ingredient Bovine Colostrum Powder that is harvested from dairy cows which are immunised with Immuron’s proprietary vaccine.

By vaccinating the cows, Immuron causes a shift in the bovine colostrum antibody composition, which is designed to confer on IMM-124E its pharmaceutical quality.

Recruitment is already underway for the ASH trial with the first three of a planned 66 patients already enrolled.

ASH has a poor prognosis and is a syndrome of progressive inflammatory liver injury associated with long-term heavy alcohol consumption. There is no approved drug for the treatment of this disease.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Thu, 15 Jan 2015 15:00:00 +1100 https://www.proactiveinvestors.com.au/companies/news/137158/immuron-starts-sponsored-phase-2-trial-for-treatment-of-alcoholic-steatohepatitis-60112.html
<![CDATA[News - Immuron Limited signs deal to commercialise alcohol-induced liver toxicity treatment ]]> https://www.proactiveinvestors.com.au/companies/news/137157/immuron-limited-signs-deal-to-commercialise-alcohol-induced-liver-toxicity-treatment-59920.html Immuron Limited (ASX:IMC) has entered into an agreement with Immune Biologics Pty Ltd to develop and commercialise its IMM-124E treatment for short-term alcohol-induced liver toxicity.

Under the agreement, Immune Biologics will carry out clinical trials designed to test the efficacy of IMM-124E.

The principle underlying these studies is that the anti-LPS activity of IMM-124E is the same underlying mechanism that governs the treatment of both non-alcoholic steatohepatitis (NASH) and alcoholic steatohepatitis (ASH), thus enabling the testing and use of IMM-124E in this third short-term clinical indication.   

Should the trials be successful, Immuron will sell IMM-124E to Immune Biologics under a worldwide license specifically for toxicity associated with short-term alcohol intake.

Immune Biologics is associated with Peter Anastasiou, Immuron’s largest shareholder through various related entities.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Tue, 06 Jan 2015 15:30:00 +1100 https://www.proactiveinvestors.com.au/companies/news/137157/immuron-limited-signs-deal-to-commercialise-alcohol-induced-liver-toxicity-treatment-59920.html
<![CDATA[News - Immuron's travel sickness remedy launched in Canada ]]> https://www.proactiveinvestors.com.au/companies/news/137156/immurons-travel-sickness-remedy-launched-in-canada-56750.html Immuron Limited (ASX:IMC) partner for the sale of its travel sickness remedy Travelan, Paladin Labs, has launched the product in Canada.

It is estimated that there are over 5 million trips made by Canadians to at-risk regions every year, and 1 in 3 Canadian vacationers have experienced, or have travelled with someone who has experienced, travellers' diarrhoea.
 
Paladin’s launch follows the signing of a distribution agreement and regulatory approval for Travelan in Canada in November 2013.

That agreement included an upfront payment to Immuron and entitles Immuron to receive certain milestone payments based on Paladin’s commercialisation success, which are in addition to the transfer price payable for each unit of product sold by Immuron to Paladin.

Paladin has a proven track record in successfully marketing and selling a range of over-the-counter products.

Immuron's global Travelan sales generated in excess of $1 million revenue for the financial year ended June 30th 2014, seven times the company’s FY2013 Travelan revenues.

Immuron is capitalised at around $15 million and also has two phase 2 clinical programs in progress for the treatment of inflamed fatty liver disease and Alcoholic Steatohepatitis.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Wed, 06 Aug 2014 15:00:00 +1000 https://www.proactiveinvestors.com.au/companies/news/137156/immurons-travel-sickness-remedy-launched-in-canada-56750.html
<![CDATA[News - Immuron travel sickness remedy generates $1M in sales ]]> https://www.proactiveinvestors.com.au/companies/news/137155/immuron-travel-sickness-remedy-generates-1m-in-sales-56091.html Immuron Limited (ASX:IMC) has generated in excess of $1 million in sales revenue from its flagship product, Travelan, for the financial year ended June 30th 2014.

These revenues are seven times the company’s FY2013 Travelan revenues.

Travelan is clinically-proven to prevent with 90% efficacy the main cause of travellers’ diarrhoea.

According to the World Tourism Organization, diarrheal illness is the most common health impairment associated with international tourism in terms of frequency and economic impact.

The direct-to-wholesale model that Immuron announced last year has substantially increased the company’s gross margins and revenues.

The stable demand for Travelan in the market following a significant price increase is testament both to the quality of the product and to its benefit.

Immuron is capitalised at around $14 million.

Immuron also has two phase 2 clinical programs - one for the treatment of inflamed fatty liver disease, known as Non-Alcoholic Steatohepatitis, and an NIH-sponsored project for the treatment of Alcoholic Steatohepatitis.

Immuron’s main scientific alliances are with Hadassah Medical Center in Israel and Monash University.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Mon, 07 Jul 2014 12:30:00 +1000 https://www.proactiveinvestors.com.au/companies/news/137155/immuron-travel-sickness-remedy-generates-1m-in-sales-56091.html
<![CDATA[News - Immuron to sell travel sickness remedy in South Korea ]]> https://www.proactiveinvestors.com.au/companies/news/137154/immuron-to-sell-travel-sickness-remedy-in-south-korea-55106.html Immuron Limited (ASX:IMC) has entered into an agreement with DB Pharm Korea Co. for the sale of its travel sickness remedy Travelan® in South Korea.

Under the agreement DB Pharm Korea is granted exclusive rights to market, distribute, and sell Travelan® in South Korea, and requires DB Pharm Korea to comply with specified annual minimum order obligations.

DB Pharm Korea is also required to attain regulatory approval from the Korean Food and Drug Administration for the sale of Travelan® as an over-the-counter drug in South Korea.

An application for this is currently being prepared and approval is expected within 12 months.

DB Pharm intends to market Travelan® nationwide through pharmacies, targeting both overseas travellers, especially to south-east Asian countries including China, and local patients suffering from travellers' diarrhoea.

Travelan® is clinically-proven to prevent the main cause of travellers’ diarrhoea, with 90% efficacy.

According to the World Tourism Organization, diarrheal illness is by far the most common health impairment associated with international tourism in terms of frequency and economic impact.

Fifty million people travel each year from developed countries to developing countries, and up to 50% of these travellers report being affected by the condition during the first two weeks of their stay.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Wed, 21 May 2014 13:00:00 +1000 https://www.proactiveinvestors.com.au/companies/news/137154/immuron-to-sell-travel-sickness-remedy-in-south-korea-55106.html
<![CDATA[News - Immuron to raise $9.66 million in fully underwritten rights issue ]]> https://www.proactiveinvestors.com.au/companies/news/137153/immuron-to-raise-966-million-in-fully-underwritten-rights-issue-52121.html Immuron Limited (ASX:IMC) is set to raise $9.66 million via a fully underwritten rights issue at $0.005 per share to fund Phase 2B clinical trials for the treatment of Non-Alcoholic SteatoHepatitis.

Proceed will also be used to continue the global commercialisation of its travel sickness product Travelan, repay debt and fund development and commercialisation of other Immuron products.

Patersons Securities is lead manager and underwriter to the offer, with BBY Limited acting as broker.

Shares will be offered on the basis of 11 new shares priced at $0.005 each for every 6 shares held.

Immuron's first product Travelan is approved, in the marketplace generating sales, with growing revenues.

And the company's proposed treatment for Non-Alcoholic SteatoHepatitis, or fatty liver, is headed towards a $3.2 billion market by 2016 in the US alone, with no current treatment.

Immuron is capitalised at around $12 million, and offers significant potential upside.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Wed, 22 Jan 2014 15:40:00 +1100 https://www.proactiveinvestors.com.au/companies/news/137153/immuron-to-raise-966-million-in-fully-underwritten-rights-issue-52121.html
<![CDATA[News - Immuron Limited heads to market ]]> https://www.proactiveinvestors.com.au/companies/news/137152/immuron-limited-heads-to-market-52017.html Immuron Limited (ASX: IMC) is heading to market with a capital raising, with the Australian Stock Exchange granting the company a trading halt this morning.

Immuron's shares are currently in pre-open.

Towards the end of 2013 the company obtained approval to sell its Travelan diarrhoea preventative in Canada, through partner Paladin Labs Inc.

The authorization granted is for tablets comprising 200 milligrams of Immuron’s hyperimmune bovine colostrum.

In Canada, Travelan is classified as a natural health product and will be available to patients over the counter without prescription.

The halt will remain in place until the opening of trade on Wednesday 22nd January 2014, or earlier if an announcement is made to the market.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Mon, 20 Jan 2014 13:00:00 +1100 https://www.proactiveinvestors.com.au/companies/news/137152/immuron-limited-heads-to-market-52017.html
<![CDATA[News - Immuron Limited receives green light for product sales in Canada ]]> https://www.proactiveinvestors.com.au/companies/news/137151/immuron-limited-receives-green-light-for-product-sales-in-canada-50137.html Immuron Limited's (ASX:IMC) shares should open higher after obtaining approval to sell its Travelan diarrhea preventitive in Canada, through partner Paladin Labs Inc.

The authorization granted is for tablets comprising 200 milligrams of Immuron’s hyperimmune bovine colostrum.

In Canada, Travelan is classified as a natural health product and will be available to patients over the counter without prescription.

Paladin Labs will be able to claim on the product package that Travelan is "Clinically Proven to Help Reduce the Risk
of Travellers’ Diarrhea".

As Immuron continues to expand the Travelan global franchise, approval in Canada represents a significant milestone and is expected to be followed by additional licensing agreements and product approvals in other regions.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Wed, 13 Nov 2013 13:20:00 +1100 https://www.proactiveinvestors.com.au/companies/news/137151/immuron-limited-receives-green-light-for-product-sales-in-canada-50137.html
<![CDATA[News - Immuron receives U.S. FDA approval to trial new liver disease treatment ]]> https://www.proactiveinvestors.com.au/companies/news/137150/immuron-receives-us-fda-approval-to-trial-new-liver-disease-treatment-49991.html Immuron Limited (ASX: IMC) is set to trade higher after receiving investigational new drug clearance from the US Food and Drug Administration to commence a clinical trial of its bovine colostrum-derived therapeutic for the treatment of a liver disease, alcoholic steatohepatitis, or ASH.

Immuron is also in preparation for Phase IIb clinical trials of non-alcoholic steatohepatitis, or NASH.

Notably, the principal investigator for its NASH trial has been awarded a National Institutes of Health grant to conduct a clinical trial for ASH.

This trial will be conducted by the TREAT consortium, one of the world’s leading collaborations for clinical research into fatty liver diseases.

TREAT consortium's ASH trial is expected to provide Immuron with additional guidance for its NASH trials commencing next year.

NASH and ASH arise from different causes; both result in liver damage potentially leading to liver fibrosis, liver cirrhosis hepatic carcinoma.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Fri, 08 Nov 2013 12:20:00 +1100 https://www.proactiveinvestors.com.au/companies/news/137150/immuron-receives-us-fda-approval-to-trial-new-liver-disease-treatment-49991.html
<![CDATA[News - Immuron launches fully underwritten A$1.86M capital raising ]]> https://www.proactiveinvestors.com.au/companies/news/137149/immuron-launches-fully-underwritten-a186m-capital-raising-41326.html Immuron (ASX: IMC) will raise A$1.86 million in a fully underwritten renounceable pro-rata rights offer.

The company is offering three new shares for every two shares held at $0.003 per share under the rights offer, which is being fully underwritten by Patersons Securities.

Immuron will issue around 621.3 million shares.

The company is advancing the development of its pipeline of oral immunotherapeutic products.

Most recently, Immuron further demonstrated the effectiveness of its IMM-529 in preventing the antibiotic-associated infection, Clostridium difficile, in mice.

Clostridium difficile is the most serious cause of antibiotic-associated diarrhoea (AAD) and can lead to a severe infection of the colon that often results from eradication of the normal gut flora by antibiotics.

Additional studies are planned to investigate IMM-529’s efficacy in treating Clostridium difficile post-infection, as well as to support patent applications and a human clinical trial.

Immuron could begin clinical trials as early as this year.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Wed, 27 Mar 2013 11:50:00 +1100 https://www.proactiveinvestors.com.au/companies/news/137149/immuron-launches-fully-underwritten-a186m-capital-raising-41326.html
<![CDATA[News - Immuron Limited to go to market ]]> https://www.proactiveinvestors.com.au/companies/news/137148/immuron-limited-to-go-to-market-41181.html Immuron Limited (ASX: IMC) is in pre-open this morning after the ASX granted the company a trading halt, pending a capital raising announcement.

Immuron is a biopharmaceutical company focused on oral immunotherapy treatments using dairy-derived antibody products for humans.

The halt will last until the earlier of an announcement being made to the market, or the opening of trade on Wednesday 27th March 2013.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Mon, 25 Mar 2013 09:30:00 +1100 https://www.proactiveinvestors.com.au/companies/news/137148/immuron-limited-to-go-to-market-41181.html
<![CDATA[News - Immuron has further success with antibiotic-associated infection prevention drug ]]> https://www.proactiveinvestors.com.au/companies/news/137147/immuron-has-further-success-with-antibiotic-associated-infection-prevention-drug-40346.html Immuron (ASX: IMC) has further demonstrated the effectiveness of its IMM-529 in preventing the antibiotic-associated infection, Clostridium difficile, in mice.

Clostridium difficile is the most serious cause of antibiotic-associated diarrhoea (AAD) and can lead to a severe infection of the colon that often results from eradication of the normal gut flora by antibiotics.

Importantly, the most recent results, combined with earlier ones, demonstrate the significance of IMM-529 as a prophylaxis for Clostridium difficile infection.

The most recent study, conducted by Monash University, looked at the survival rate, weight loss and histopathology of mice treated with IMM-529 prior to being exposed to the Clostridium difficile bacteria.

The results demonstrate a strong rationale for continuing the development of a prophylaxis product, and strengthen the intellectual property around this product.

Additional studies are planned to investigate IMM-529’s efficacy in treating Clostridium difficile post-infection, as well as to support patent applications and a human clinical trial.

Immuron could begin clinical trials as early as this year.


Market opportunity

Clostridium difficile infections are increasing due to the widespread use of antibiotics.

The most recently approved product to treat Clostridium difficile infection is a macrolide antibiotic drug that demonstrates a comparable efficacy to vancomycin, the previous treatment of choice.

Both these treatments cost in excess of US$1,800 (A$1,772) per person for a 10 day treatment.

There is no preventative product currently available.

Clostridium difficile infections result in an estimated annual economic burden of more than US$10 billion globally.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Mon, 04 Mar 2013 15:30:00 +1100 https://www.proactiveinvestors.com.au/companies/news/137147/immuron-has-further-success-with-antibiotic-associated-infection-prevention-drug-40346.html
<![CDATA[News - Immuron enhances balance sheet by A$1.4m to continue commercial rollout of Travelan® ]]> https://www.proactiveinvestors.com.au/companies/news/137146/immuron-enhances-balance-sheet-by-a14m-to-continue-commercial-rollout-of-travelan--30204.html Immuron (ASX: IMC) has now raised a total of A$1.4 million through a recent share purchase plan and earlier private placement, with the company now in a good cash position to continue the commercial roll-out of the travellers' diarrhoea product known as Travelan®.

The product is a unique oral preventative against bacteria, with clinical studies showing that the product provides protection against the main cause of traveller’s diarrhoea in 90% of consumers who use it.

Highlighting the globalisation of Travelan®, the product is currently approved in Australia, New Zealand and South Africa, with the potential global market being identified as US$650 million annually.

The capital injection means Immuron is also well placed to advance ongoing discussions with potential licensees for its Non-Alcoholic Steatohepatitis (NASH) and Fatty Liver product, IMM-124E.

NASH is one of the most common liver diseases in the western world. It is associated with obesity, diabetes and hyperlipidaemia.

Earlier this year Immuron received the all clear from the United States Food and Drug Administration to proceed with a Phase 2b clinical trial of IMM-124E.

IMM-124E has the potential to be the first available and approved treatment for NASH patients in the world and the only product candidate to date that addresses the pathogenesis of the disease, representing an extremely lucrative opportunity for Immuron.

Based on the data generated to date, IMM-124E has a high safety profile and is able to elicit a response in many fatty liver/NASH parameters including insulin resistance and elevated serum cholesterol.


Proactive Investors is a market leader in the investment news space, providing ASX “Small and Mid-cap” company news, research reports, StockTube videos and One2One Investor Forums.

]]>
Mon, 18 Jun 2012 09:40:00 +1000 https://www.proactiveinvestors.com.au/companies/news/137146/immuron-enhances-balance-sheet-by-a14m-to-continue-commercial-rollout-of-travelan--30204.html
<![CDATA[News - Immuron: globalisation of Travelan® continues with over the counter potential in Canada ]]> https://www.proactiveinvestors.com.au/companies/news/137145/immuron-globalisation-of-travelan-continues-with-over-the-counter-potential-in-canada-29684.html Immuron (ASX: IMC) and partner Paladin Labs Inc (TSE: PLB) have made some major steps forward in Canada for the commercialisation of the travellers' diarrhea product known as Travelan®.

Paladin has filed a Non‐Traditional Product Licence Application that has been accepted for review by Health Canada for Travelan®, as an over-the-counter product.

The product is a unique oral preventative against bacteria, with clinical studies showing that the product provides protection against the main cause of traveller’s diarrhea in 90% of consumers who use it.

Paladin obtained the exclusive rights to market and sell Travelan in Canada, Latin America and Sub‐Saharan Africa from Immuron in November 2011. Up to 50% of people who travel to developing countries will contract the disease.

According to the Public Health Agency of Canada, travellers’ diarrhea is the most common illness that affects travellers, especially those travelling to areas such as Central and South America, Mexico, Africa, the Middle East and Asia.

Highlighting the globalisation of Travelan®, the product is currently approved in Australia, New Zealand and South Africa, with the potential global market being identified as US$650 million annually.

 

Proactive Investors is a market leader in the investment news space, providing ASX “Small and Mid-cap” company news, research reports, StockTube videos and One2One Investor Forums.

]]>
Mon, 04 Jun 2012 12:00:00 +1000 https://www.proactiveinvestors.com.au/companies/news/137145/immuron-globalisation-of-travelan-continues-with-over-the-counter-potential-in-canada-29684.html
<![CDATA[News - Immuron secures distributor for Travelan® in southeast Asian markets ]]> https://www.proactiveinvestors.com.au/companies/news/137144/immuron-secures-distributor-for-travelan-in-southeast-asian-markets-28708.html Immuron (ASX: IMC) has entered into an agreement with specialist distributor IntegraMed Asia for the sale of the company’s Travelan® product in five southeast Asian markets which collectively attracted over 44 million tourists in 2010.

Travelan® is a novel, over the counter product that is up to 90% effective in preventing travellers’ diarrhoea.

This is an important milestone for Immuron, marking the start of first sales of the product in Thailand, Hong Kong, Cambodia, Vietnam and Laos – countries in which travellers’ diarrhoea is endemic.

IntegraMed Asia is a licensed seller in the Indo‐China market with branches in Bangkok, Singapore and the United Kingdom.

Under the distribution agreement, IntegraMed Asia is required to attain regulatory approval for the sale of Travelan® in its licensed countries and to sell specified minimum volumes.

The company has already begun the regulatory approval process.


Funding agreement

Earlier this year Immuron secured a A$1.5 million (C$1.5 million) funding agreement with Paladin Labs to continue expansion of its Travelan® product into other territories.

Under the agreement, the initial drawdown will be C$1 million, including a coupon rate of 10% and not repayable until three years from the date of initial drawdown.

Under a licence agreement signed by both parties in late November, Paladin receives exclusive rights to commercialise Travelan in certain territories, including Canada, Latin America and sub-Saharan Africa.

Immuron received an upfront licence fee of C$500,000 for those territories from Paladin and will receive additional performance milestone payments over the term of the licence.


Proactive Investors is a market leader in the investment news space, providing ASX “Small and Mid-cap” company news, research reports, StockTube videos and One2One Investor Forums.

]]>
Thu, 10 May 2012 13:20:00 +1000 https://www.proactiveinvestors.com.au/companies/news/137144/immuron-secures-distributor-for-travelan-in-southeast-asian-markets-28708.html
<![CDATA[News - Immuron enters A$1.4m funding agreement to expand Travelan into other territories ]]> https://www.proactiveinvestors.com.au/companies/news/137143/immuron-enters-a14m-funding-agreement-to-expand-travelan-into-other-territories--24149.html Immuron (ASX: IMC) has secured a A$1.4 million (C$1.5 million) funding agreement with Paladin Labs which the company will use to continue expansion of its Travelan® product into other territories.

Travelan® is a novel, over the counter product that is up to 90% effective in preventing travellers’ diarrhoea.

Under the agreement, the initial drawdown will be C$1 million, including a coupon rate of 10% and not repayable until three years from the date of initial drawdown.

Paladin has the right to convert all or part of the funds advanced into fully paid ordinary Immuron shares at an agreed conversion price of $A0.0473 per share.

Under a licence agreement signed by both parties in late November, Paladin receives exclusive rights to commercialise Travelan in certain territories, including Canada, Latin America and sub-Saharan Africa.

Immuron received an upfront licence fee of C$500,000 for those territories from Paladin and will receive additional performance milestone payments over the term of the licence.

]]>
Mon, 16 Jan 2012 11:00:00 +1100 https://www.proactiveinvestors.com.au/companies/news/137143/immuron-enters-a14m-funding-agreement-to-expand-travelan-into-other-territories--24149.html
<![CDATA[News - Immuron receives green light to begin clinical liver disease trial in the U.S. ]]> https://www.proactiveinvestors.com.au/companies/news/137142/immuron-receives-green-light-to-begin-clinical-liver-disease-trial-in-the-us--23969.html Immuron (ASX: IMC) has received the all clear from the United States Food and Drug Administration to proceed with a Phase 2b clinical trial of its bovine colostrum-derived therapeutic, IMM-124E, for the treatment of Non-Alcoholic Steatohepatitis (NASH) and Fatty Liver.

Importantly, the company’s Investigational New Drug submission to begin the double-blind, placebo-controlled and dose ranging trial was cleared by the United States Food and Drug Administration without the authority raising any concerns.

The trial – which will be undertaken at sites in the United States, Australia and Israel – primarily aims to determine the safety and efficacy of Immuron’s orally administered IMM-124E in patients with biopsy-confirmed NASH.

IMM-124E has the potential to be the first available and approved treatment for NASH patients in the world and the only product candidate to date that addresses the pathogenesis of the disease, representing an extremely lucrative opportunity for Immuron.

Significantly, this market – worth US$4.4 billion (A$4.3 billion) in the U.S. alone – has no existing approved competitors, according to Immuron.

NASH is one of the most common liver diseases in the western world. It is associated with obesity, diabetes and hyperlipidaemia.

It affects approximately 5% of the lean population, 20% of the obese population and 50% of morbidly obese people.

It resembles alcoholic liver disease but occurs in people who drink little or no alcohol. The major feature in NASH is fat in the liver along with inflammation and damage.

NASH can be severe and can lead to cirrhosis, in which the liver is permanently damaged and scarred and no longer able to function properly.

Based on the data generated to date, IMM-124E has a high safety profile and is able to elicit a response in many fatty liver/NASH parameters including insulin resistance and elevated serum cholesterol.

Immuron revealed late last year it is also in early discussions with potential global licensees.

]]>
Tue, 10 Jan 2012 11:31:00 +1100 https://www.proactiveinvestors.com.au/companies/news/137142/immuron-receives-green-light-to-begin-clinical-liver-disease-trial-in-the-us--23969.html
<![CDATA[News - Immuron partners with Harvard Medical School to test its technology in cancer patients ]]> https://www.proactiveinvestors.com.au/companies/news/137141/immuron-partners-with-harvard-medical-school-to-test-its-technology-in-cancer-patients-23538.html Immuron (ASX: IMC) has entered into a research agreement with the primary paediatric teaching hospital of Harvard Medical School, to test the effect of the company’s colostrum product in people undergoing radiation therapy.

The partnership with the Dana-Farber Cancer Institute and Children’s Hospital Boston will test how the colostrum product can help reduce the side effects of cancer treatments, and extend to how it may treat newborn lung inflammation.

Early data generated from animal studies has been encouraging to date and has provided the impetus for ongoing research.

Under the agreement, Immuron will retain rights to any data generated relating to its technology.

Immuron is developing oral immunotherapy treatments using dairy derived antibody products for use in humans.

The company’s proprietary dairy derived polyclonal antibody platform produces antibodies potentially suited to treat a wide range of diseases including infectious disease (bacterial and viral), cancers and chronic inflammatory diseases. 

These antibodies are designed for delivery to the gastro-intestinal tract, the upper respiratory tract and/or topically, as required.

Importantly, the production of dairy colostrum- derived polyclonal antibodies is cost efficient, especially when compared to monoclonal antibodies.

]]>
Fri, 16 Dec 2011 13:40:00 +1100 https://www.proactiveinvestors.com.au/companies/news/137141/immuron-partners-with-harvard-medical-school-to-test-its-technology-in-cancer-patients-23538.html
<![CDATA[News - Immuron eyes US$4.4b fatty liver disease market with new drug application ]]> https://www.proactiveinvestors.com.au/companies/news/137140/immuron-eyes-us44b-fatty-liver-disease-market-with-new-drug-application-21653.html Immuron (ASX: IMC) has submitted an Investigational New Drug application to the U.S. Food and Drug Administration for its proprietary IMM-124E fatty liver disease product in an effort to break into the Non-Alcoholic Steatohepatitis (NASH) market.

Significantly, this market – worth US$4.4 billion (A$4.2 billion) in the U.S. alone – has no existing approved competitors, according to Immuron.

The United States National Centre for Infection Control has predicted that by 2025, 25 million Americans will suffer from NASH, with very few current treatment options.

At present approximately 5% of Americans are affected, with similar rates in Australia. It is estimated that between 10 and 20% of the population have fatty liver, with an estimated 75% of obese individuals being at risk of developing fatty liver.

Based on the data generated to date, IMM-124E has a high safety profile and is able to elicit a response in many fatty liver/NASH parameters including insulin resistance and elevated serum cholesterol.

Immuron is moving towards Phase 2b clinical trials to further test the safety and efficacy of the drug.

The trial will be a dose ranging, placebo controlled, double blind multi-centre study in NASH patients receiving six months of active treatment involving sites in Australia, the United States and Israel.

Immuron is also in early discussions with potential global licensees.

]]>
Mon, 07 Nov 2011 10:00:00 +1100 https://www.proactiveinvestors.com.au/companies/news/137140/immuron-eyes-us44b-fatty-liver-disease-market-with-new-drug-application-21653.html
<![CDATA[News - Immuron completes recruitment for HIV trial ]]> https://www.proactiveinvestors.com.au/companies/news/137139/immuron-completes-recruitment-for-hiv-trial-2601.html Australian biopharmaceutical company focused on antigen-primed, dairy-derived health products, Immuron (ASX: IMC, OTCQX: IMROY) has completed recruitment for a multicentre HIV adjunct therapy trial in Australia.

Immuron has an antibody-based ‘Bioguard’ formulation currently in human trials to investigate its efficacy in helping control the abnormal gastrointestinal inflammation associated HIV (Human Immunodeficiency Virus) infections.

Professor Colin Chapman, chairman of Immuron said this was a significant milestone. “The end of the recruiting phase is often a very difficult phase and is quite significant. As clinical trials are planned around the treatment length for each individual, once the last volunteer is on the program the endpoint of the trial can be reliably predicted," he said.

Chapman said it was believed this formulation will slow progress of the disease when used either alone or in combination with an anti-retroviral drug.

The Australian based study is a multicenter trial sponsored by the internationally recognised National Centre for HIV Epidemiology and Clinical Research of the University of New South Wales.

]]>
Mon, 21 Sep 2009 07:57:00 +1000 https://www.proactiveinvestors.com.au/companies/news/137139/immuron-completes-recruitment-for-hiv-trial-2601.html
<![CDATA[News - Immuron deals itself into influenza treatment market, with global pharma company ]]> https://www.proactiveinvestors.com.au/companies/news/137138/immuron-deals-itself-into-influenza-treatment-market-with-global-pharma-company-2234.html ASX listed drug developer, Immuron (ASX: IMC) has dealt itself very firmly into the high profile, and potentially high return influenza treatment market.

Immuron has entered into discussions with a top-25 global pharmaceutical company, with a potential joint development of Immuron’s influenza treatment and prevention product.

As indicated previously, Immuron has achieved very positive results in pre-clinical (animal) trials on its influenza product.

Clearly, this is an important step in the evolution of Immuron as it scientifically and commercially progresses its new influenza product.

Immuron is continuing to attract interest in assisting with the scientific development and commercialisation of products from its pipeline.

]]>
Thu, 13 Aug 2009 07:41:00 +1000 https://www.proactiveinvestors.com.au/companies/news/137138/immuron-deals-itself-into-influenza-treatment-market-with-global-pharma-company-2234.html
<![CDATA[News - Immuron's influenza treatment product gaining momentum ]]> https://www.proactiveinvestors.com.au/companies/news/137137/immurons-influenza-treatment-product-gaining-momentum-2209.html Immuron (ASX: IMC) has commenced a drug development program for its prospective influenza treatment product using a novel approach.

Proof in principle in both treatment and prevention roles has been shown to successfully, in accepted animal (mouse) models of human influenza using a mouse adapted H1N1 influenza virus. Disease was found to be treated or stopped in progress or infection prevented for up to 7 days.

Commonwealth funding has been approved for further development of the concept enabling use of current human influenza strains and the swine flu strain.

Human clinical trials are expected to be conducted in 2010. A patent is lodged and pending on the technology.

Immuron's product is expected to be an Over-the-counter (OTC) product with the potential to commercialise / partner with a larger company with OTC interests. Immuron is already discussing the technology with several commercial parties with a view to licensing or partnering.

The product is based on dairy derived antibodies that neutralise virus and can be given orally or as a spray.

]]>
Tue, 11 Aug 2009 13:15:00 +1000 https://www.proactiveinvestors.com.au/companies/news/137137/immurons-influenza-treatment-product-gaining-momentum-2209.html